Related Experiment Video

Updated: Jul 14, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[The diabetic child and the specifics of insulin therapy]

M Dirlewanger1, L Perrenoud, M Castellsague-Perolini

  • 1Unité d'endocrinologie et diabétologie pédiatriques, Département de pédiatrie, HUG, Genève. Mirjam.Dirlewanger@hcuge.ch

Revue Medicale Suisse
|May 29, 2007
PubMed

Insights

Type 1 diabetes incidence is rising in young children. Advances in insulin therapy and glucose monitoring have improved quality of life and metabolic control, reducing severe hypoglycemia. Future prevention strategies are emerging.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 1 diabetes incidence shows a significant annual increase of 23.8% in young children in Switzerland over the past decade.
  • Recent advancements in insulin analogue development (rapid-acting and long-acting) have marked substantial progress in diabetes management.
  • Improved therapeutic approaches, including multiple daily insulin injections, carbohydrate counting, and continuous subcutaneous insulin infusion (CSII), have enhanced patient quality of life and daily flexibility.

Purpose of the Study:

  • To review the progress in Type 1 diabetes management.
  • To highlight the impact of new therapeutic strategies on patient outcomes.
  • To discuss future directions in diabetes prevention and treatment.

Main Methods:

  • Review of recent advancements in insulin therapy and glucose monitoring technologies.
  • Analysis of the impact of continuous subcutaneous insulin infusion (CSII) on glycemic control and quality of life.
  • Exploration of emerging immunomodulation strategies for diabetes prevention.

Main Results:

  • Significant improvements in quality of life and daily flexibility observed with advanced insulin therapies.
  • Decreased incidence of severe hypoglycemic events concurrent with improved metabolic control.
  • Continuous glucose monitoring integrated with insulin pumps represents a significant step toward an artificial pancreas.

Conclusions:

  • Modern therapeutic strategies have substantially improved the management and outcomes of Type 1 diabetes in children.
  • Technological integration, such as closed-loop systems, offers promising avenues for enhanced diabetes control.
  • Immunomodulation presents a hopeful future for secondary and tertiary prevention of Type 1 diabetes.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...